CD86 and myeloid sarcoma: While there are studies showing that CD86 is overexpressed in PBMCs at all stages of MS compared with the HC [32], to the best of our knowledge, there is no data showing how ocrelizumab affects expression of CD86 in PBMCs of patients with MS.